Neoadjuvant immunotherapy shows promise in multiple cancer types

Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching the surface of what is possible, according to a review article co-authored by several current and former investigators from the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Kimmel Cancer Center.

Related Keywords

Lily Ramsey ,Johns Hopkins ,Suzanne Topalian ,Kellie Smith ,Patrick Forde ,Mark Yarchoan ,Johns Hopkins Kimmel Cancer Center ,Johns Hopkins Melanoma Skin Cancer Program ,Bloomberg Kimmel Institute For Cancer Immunotherapy ,Kimmel Institute ,Johns Hopkins Kimmel Cancer ,Skin Cancer Program ,Cancer Cell ,Drew Pardoll ,Leisha Emens ,Cancer ,Surgery ,Breast Cancer ,Ancer Immunotherapy ,Fell ,It ,Immunotherapy ,Lung Cancer ,Melanoma ,Microscope ,Mh ,Research ,Skin ,Humor ,